Disease · HP_0010992
Stress urinary incontinence
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Stress urinary incontinence. Diseases, record HP_0010992. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0010992
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Stress urinary incontinence
- Open Targets ID
- HP_0010992
- Highest stage of its drugs
- Approval, for 1 of its 21 drugs, from EMA Human Drugs
Source Open Targets
Drugs21
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DULOXETINE | CHEMBL1175 | Small molecule | Approval | EMA Human Drugs | 13 | 12 | 12 | Drugs and targets |
| ILTAMIOCEL | CHEMBL4650237 | Cell | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IMIPRAMINE | CHEMBL11 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets | |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ESTRIOL | CHEMBL193482 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEFAPIXANT | CHEMBL3716057 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LETIBOTULINUMTOXINA | CHEMBL3707322 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| ORFORGLIPRON | CHEMBL4446782 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 21
See all 21 drugsTargets19
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | 5 | Norepinephrine transporter inhibitor | Approval | https://conductscience.org/library/genes/6530 | Drugs and targets |
| AR | Androgen receptor | 3 | Androgen Receptor agonist; Androgen Receptor modulator | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 3 | Serotonin transporter inhibitor | Approval | https://conductscience.org/library/genes/6532 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 3 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| CHRM2 | Muscarinic acetylcholine receptor M2 | 1 | Muscarinic acetylcholine receptor M2 antagonist | Phase 2 | https://conductscience.org/library/genes/1129 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 1 | Muscarinic acetylcholine receptor M3 antagonist | Phase 2 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| ESR2 | Estrogen receptor | 1 | Estrogen receptor modulator | Phase 3 | https://conductscience.org/library/genes/2100 | Drugs and targets |
| P2RX3 | P2X purinoceptor 3 | 1 | P2X purinoceptor 3 antagonist | Phase 3 | https://conductscience.org/library/genes/5024 | Drugs and targets |
1 to 10 of 19
See all 19 targetsTrials36
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03241342 | Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence | Phase 2 | 491 | 2020-11-12 | Stress Urinary Incontinence | ENOBOSARM | Its record names the disease | ClinicalTrials.gov |
| NCT04193176 | Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) | Phase 3 | 376 | 2023-09-22 | Chronic Cough | GEFAPIXANT | Its record names the disease | ClinicalTrials.gov |
| NCT02906683 | Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence | Phase 2 | 337 | 2024-09-26 | Stress Urinary Incontinence | TAS-303 | Its record names the disease | ClinicalTrials.gov |
| NCT01893138 | Autologous Muscle Derived Cells for Female Urinary Sphincter Repair | Phase 3 | 311 | 2023-01-05 | Stress Urinary Incontinence | ILTAMIOCEL | Its record names the disease | ClinicalTrials.gov |
| NCT04171531 | Sling vs Botox for Mixed Incontinence | Phase 3 | 150 | 2025-03-20 | Urinary Incontinence, Stress, Urinary Incontinence, Urge | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT00904618 | Safety and Efficacy Study on the Implantation of the Tension-Free Vaginal Tape (TVT-Secur) Under Local Anesthesia | Phase 2 | 48 | 2009-05-19 | Urinary Stress Incontinence | LIDOCAINE | Its record names the disease | ClinicalTrials.gov |
| NCT01042236 | Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients | Phase 2 | 22 | 2011-07-01 | Stress Urinary Incontinence | FESOTERODINE | Its record names the disease | ClinicalTrials.gov |
| NCT02658448 | GTx-024 as a Treatment for Stress Urinary Incontinence in Women | Phase 2 | 19 | 2021-02-01 | Stress Urinary Incontinence | ENOBOSARM | Its record names the disease | ClinicalTrials.gov |
| NCT03102645 | Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter? | Phase 1 | 16 | 2021-02-12 | Urinary Incontinence, Stress, Fecal Incontinence | IMIPRAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00190905 | Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions. | Phase 4 | 4,000 | Stress Urinary Incontinence | DULOXETINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 36
See all 36 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Gefapixant vs Placebo: deaths from any cause | 0 of 186 | 0 of 190 | 376 | NCT04193176 | Trial comparisons |
| Gefapixant vs Placebo: serious adverse events | 3 of 185 | 2 of 190 | 375 | NCT04193176 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary | 103 of 198 | 52 of 97 | 295 | NCT01893138 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With 0 or 1 Stress Incontinence Episodes Based on 3 Day Diary Records at 12 Months | 53 of 198 | 22 of 97 | 295 | NCT01893138 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With at ≥ 75% Reduction in Stress Incontinence Episodes From Baseline at 12 Months | 73 of 198 | 30 of 97 | 295 | NCT01893138 | Trial comparisons |
| Botox A vs Mid-Urethral Sling: deaths from any cause | 0 of 71 | 0 of 69 | 140 | NCT04171531 | Trial comparisons |
| Botox A vs Mid-Urethral Sling: serious adverse events | 3 of 71 | 8 of 69 | 140 | NCT04171531 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With at ≥ 75% Reduction in Stress Incontinence Episodes From Baseline at 12 Months (Prior Surgery Participants Only) | 20 of 50 | 4 of 25 | 75 | NCT01893138 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With 0 or 1 Stress Incontinence Episodes Based on 3 Day Diary Records at 12 Months (Prior Surgery Participants Only) | 14 of 50 | 3 of 25 | 75 | NCT01893138 | Trial comparisons |
| Imipramine vs Placebo: deaths from any cause | 0 of 16 | 0 of 16 | 32 | NCT03102645 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 39222649 | RESULT | 1 | PubMed |
| 40323617 | DERIVED | 1 | PubMed |
| 39282854 | DERIVED | 1 | PubMed |
| 39167201 | DERIVED | 1 | PubMed |
| 38979756 | DERIVED | 1 | PubMed |
| 38212101 | DERIVED | 1 | PubMed |
| 34242627 | DERIVED | 1 | PubMed |
| 28734829 | DERIVED | 1 | PubMed |
| 24258099 | DERIVED | 1 | PubMed |
| 19929591 | DERIVED | 1 | PubMed |
1 to 10 of 12
See all 12 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0010992
GET https://conductscience.org/api/diseases/v1/HP_0010992/drugs?page=2